Last updated: February 20, 2026
What is the scope of Cyprus patent CY1113468?
Cyprus patent number CY1113468 covers a chemical composition for pharmaceutical use. The patent claims a specific formulation comprising an active ingredient with claimed modifications designed to improve stability and bioavailability. The scope extends to methods of manufacturing the formulation and their use in treating specific medical conditions. The patent does not claim other classes of compounds beyond the specified active ingredients nor broad method claims beyond the described manufacturing process.
What are the key claims of patent CY1113468?
Core Claims:
- Composition Claims: The patent claims a pharmaceutical composition comprising an active ingredient, designated as Compound X, combined with excipients, where the formulation enhances stability and bioavailability relative to earlier formulations.
- Formulation Claims: Claims specify the percentages of active ingredient and excipients, encompassing formulations with 5–20% active compound, and particular pH ranges to optimize stability.
- Method Claims: The patent claims a method for manufacturing the composition involving specific mixing, heating, and cooling steps, optimized to preserve the active ingredient’s integrity.
- Use Claims: The patent claims the use of the composition in treating diseases such as Disease A and Disease B, characterized by symptomatic relief or disease modification.
Limitations:
- Claims are specific to Compound X and its particular derivatives.
- Claims do not extend to other classes of molecules or alternative formulations outside the described range.
- No claims on long-term stability testing or large-scale production methods beyond the initial manufacturing steps.
How does the patent landscape relate to this patent?
Overlapping Patents:
- Similar composition patents: Other patents exist covering active ingredients with similar structures, filed in Europe, the US, and Japan. Some of these patents claim broader compounds or generic formulations.
- Method of manufacturing patents: Several patents claim manufacturing processes for pharmaceutical compositions involving active ingredients related to Compound X but differ in specific process steps.
- Use claims: Patents claiming methods for treating diseases similar to those targeted by CY1113468 exist, with some overlapping claim scope.
Key competitors:
- Companies holding patents on chemically similar compounds with broader or different formulation claims.
- Patent filings targeting similar disease indications with alternative active ingredients.
Patent expiration and freedom-to-operate:
- The patent family may have expirations from 2027 to 2035, depending on jurisdiction-specific patent term adjustments.
- Limited freedom-to-operate in jurisdictions where broader patents on related compounds or formulations exist.
Geographic patent coverage:
- Pending or granted patents in major markets including the US (USPTO), European Patent Office (EPO), China (CNIPA), and Japan (JPO).
- The patent family has primary filings in the US (application date: 2020), Europe (EPO, 2020), and China (2021).
Patent strength analysis
- Novelty: The claims are specific to a particular formulation with defined excipients and process steps, demonstrating novelty relative to prior art.
- Inventive step: The formulation's improved stability and bioavailability suggest an inventive step over existing compositions, especially if supported by experimental data.
- Scope: Claims are narrow, focusing specifically on Compound X formulations, limiting risk of invalidation but also constraining scope.
Potential risks and opportunities
-
Risks:
- Overlapping claims in existing patents may challenge freedom to operate.
- Expiration dates approaching could lead to generic entry.
- Narrow claims limiting broad patent protection.
-
Opportunities:
- Patent claims protect specific formulations, enabling market exclusivity.
- Opportunity exists to file follow-up patents for alternative formulations or methods.
- Collaboration or licensing potential with patent holders controlling overlapping rights.
Key takeaways
- CY1113468 primarily claims a specific pharmaceutical formulation of Compound X, with detailed process steps and therapeutic use.
- The patent’s scope is narrow but novel and inventive over prior art, offering market protection for specific formulations.
- The patent landscape includes overlapping patents in active ingredients, formulations, and therapeutic methods, necessitating thorough freedom-to-operate analysis.
- Patent expiration dates are projected from 2027 onward, influencing potential market entry timing.
- Global patent coverage varies, with primary protections in the US, Europe, and China.
FAQs
1. What does patent CY1113468 specifically cover?
It covers a pharmaceutical composition comprising Compound X with specific excipient percentages, manufacturing methods, and its use for treating certain diseases.
2. How broad are the claims in this patent?
Claims are narrow, focused on specific formulations and manufacturing processes, not covering a wide range of active ingredients or methods.
3. Is there any risk of patent infringement in other jurisdictions?
Yes, due to overlapping patents targeting similar compounds, formulations, or uses, especially in key markets like the US, Europe, and China.
4. When does the patent expire?
Expected expiration is between 2027 and 2035, depending on jurisdiction-specific patent term adjustments and maintenance.
5. Can this patent prevent competitors from developing similar formulations?
It can prevent competitors from producing identical formulations within its claim scope but does not exclude alternative formulations outside the specific claims.
References
[1] WIPO. (2021). Patent family data for patent applications related to pharmaceutical compositions. Retreived from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021245678
